Edward John Allera

SCT's And Bad Evidence Generation: 4 Solutions To Combat Its Permeation Into The Drug Approval Process

Legal Innovators Interview Series - The General Counsel At Covis Pharma Discusses The World Of Pharmaceutical Approvals Around The Globe - Corporate Counsel (Podcast)

Life Sciences Executive Exchange Series - Webinar Recap

Operating At Warp Speed: Key Takeaways From COVID-19 Clinical Trials

Leaders In Life Sciences Key Takeaways

Key Business And IP Considerations For Furthering Drug Repurposing Programs

Life Sciences Playbook - Navigating Operational And Regulatory Challenges While Emerging From The COVID-19 Pandemic

Top 10 Investor Insights On Life Sciences Post-COVID-19

Increasing Revenue And Decreasing Costs As Life Sciences Companies Emerge From COVID-19

Make Your Voice Heard In Washington Amid The COVID-19 Pandemic

In The Chaos Of COVID-19 Pandemic, What Is "Current" In cGMP?

FDA's Coronavirus Triage – How Pharma Can Work With The Agency To Tackle A Pandemic

Clinical Trial Data In The Time Of COVID-19

EBook: NDA 2.0 – The Changing World Of New Drug Applications And How To Successfully Play In The Middle Ground